LY-303511


Catalog No. size PriceQuantity
M6665-2 2mg solid $113
M6665-10 10mg solid $436

Description

LY-303511, also known as NV-128 and EM 101, is a potent mTOR inhibitor. LY-303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. LY-303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. LY-303511 acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.

Product information

CAS Number: 154447-38-8

Molecular Weight: 306.36

Formula: C19H18N2O2

Synonym:

LY 303511

NV-128

EM-101

Chemical Name: 2-(1-Piperazinyl)-8-phenyl-4H-1-benzopyran-4-one

Smiles: O=C1C=C(OC2C1=CC=CC=2C1C=CC=CC=1)N1CCNCC1

InChiKey: NGAGMBNBKCDCDJ-UHFFFAOYSA-N

InChi: InChI=1S/C19H18N2O2/c22-17-13-18(21-11-9-20-10-12-21)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13,20H,9-12H2

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

LY-303511 is structurally identical to LY294002 except for a substitution of -O for -NH in the morpholine ring, and does not potently inhibit PI3K. Treatment of cells with LY-303511 causes an increase in calcein spread similar to levels of LY294002. The ability of LY-303511 to increase gap junctional intercellular communication (GJIC) does not occur concomitant with inhibition of phosphorylation of AKT as measured by immunoblotting. LY-303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via H2O2-MAPK activation and up-regulation of death receptors. SHEP-1 cells are exposed to varying concentrations of LY-303511 (LY30), TRAIL, and a combination of the two (1 h preincubation with LY-303511 followed by TRAIL for 4 hours). SHEP-1 cells are responsive to TRAIL (~10%, ~15%, and ~30% reduction in the surviving fraction at 25, 50, and 100 ng/mL, respectively); however, treatment with LY-303511 (12.5, 25, or 50 μM) has no effect on cell viability. However, incubation of cells with LY-303511 (25 μM) for 1 hour followed by 4 hours exposure to 50 ng/mL of TRAIL has a strong synergistic effect (~40% reduction in viable cells with LY-303511+TRAIL versus ~15% with TRAIL alone). LY-303511 is a negative control compound with respect to PI3K activity. In MIN6 insulinoma cells, Wortmannin (100 nM) has no effect on whole-cell outward K+ currents, but LY294002 and LY-303511 reversibly block currents in a dose-dependent manner (IC50=9.0±0.7 μM and 64.6±9.1 μM, respectively). Kv2.1 and Kv1.4 are highly expressed in beta-cells, and in Kv2.1-transfected tsA201 cells, 50 μM LY294002 and 100 μM LY-303511 reversibly inhibit currents by 99% and 41%, respectively. LY-303511 blocks currents with an IC50 of 64.6±9.1 µM, with a maximal inhibition of ~90% at 500 µM (n≥5 cells at each concentration).

In Vivo:

Intraperitoneal administration of vehicle or LY-303511 (10 mg/kg/day) is performed when tumors reach a volume of ~150 mm3, at which time 35 mice have developed a tumor. After 21 days, >15% of the mice require euthanasia because of excessive tumor growth, and these data are censored due to unreliable estimates of average tumor volume. The administration of LY-303511, 10 mg/kg/day, is sufficient to inhibit PC-3 tumor growth in vivo.

References:

  1. Shi Y, Mellier G, Huang S, White J, Pervaiz S, Tucker-Kellogg L. Computational modelling of LY303511 and TRAIL-induced apoptosis suggests dynamic regulation of cFLIP. Bioinformatics. 2013 Feb 1;29(3):347-54. doi: 10.1093/bioinformatics/bts702. Epub 2012 Dec 13. PubMed PMID: 23239672; PubMed Central PMCID: PMC3562069.
  2. Tucker-Kellogg L, Shi Y, White JK, Pervaiz S. Reactive oxygen species (ROS) and sensitization to TRAIL-induced apoptosis, in Bayesian network modelling of HeLa cell response to LY303511. Biochem Pharmacol. 2012 Nov 15;84(10):1307-17. doi: 10.1016/j.bcp.2012.08.028. Epub 2012 Sep 6. PubMed PMID: 22982511.

Products are for research use only. Not for human use.

Payment & Security

American Express Diners Club Discover JCB Mastercard PayPal Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed